Picture of Aclaris Therapeutics logo

ACRS Aclaris Therapeutics Cashflow Statement

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeSmall CapSucker Stock

Annual cashflow statement for Aclaris Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

2019
December 31st
2020
December 31st
2021
December 31st
2022
December 31st
2023
December 31st
Period Length:12 M12 M12 M12 M12 M
Source:10-K10-K10-K10-K10-K
Standards:
USG
USG
USG
USG
USG
Status:FinalFinalFinalFinalFinal
Net Income/Starting Line-161-51-90.9-86.9-88.5
Depreciation
Deferred Taxes
Non-Cash Items61.213.639.219.70.271
Unusual Items
Other Non-Cash Items
Changes in Working Capital-2.7-2.36-1.34-1.29.39
Change in Accounts Receivable
Change in Inventories
Change in Prepaid Expenses
Change in Accounts Payable
Change in Accrued Expenses
Cash from Operating Activities-96.4-38.6-52.1-67.6-78.3
Capital Expenditures-1.61-0.453-0.308-0.605-1.31
Purchase of Fixed Assets
Other Investing Cash Flow Items1076.84-16713.247.5
Acquisition of Business
Sale of Business
Sale/Maturity of Investment
Purchase of Investments
Cash from Investing Activities1066.39-16812.646.2
Financing Cash Flow Items-0.211-3.12-0.034-0.102
Other Financing Cash Flow
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities-30.318.422572.926.7
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash-21.1-13.95.2917.9-5.4